Ads
related to: pfizer covid vaccineinsights.pfizer.com has been visited by 10K+ users in the past month
Search results
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
The Motley Fool via AOL· 51 minutes agoPfizer (NYSE: PFE) investors have been through a lot of ups and downs over the past few years. If you've been on the sidelines, now could be a great time to buy the stock.
Pfizer says tweaked COVID-19 shots boost omicron protection
KRGV Rio Grande Valley· 5 days agoPfizer announced Saturday that tweaking its COVID-19 vaccine to better target the omicron variant is...
The new technology inside COVID-19 vaccines— mRNA
KRGV Rio Grande Valley· 1 day agoWhen you think of vaccines, you may think about traditional vaccines with weak or inactive parts of a virus to trigger an immune response. Today...
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says
Reuters· 21 hours agoVaccine makers should consider targeting one of the currently dominant JN.1 variants and...
How Moderna’s newly approved RSV vaccine could impact 2024 revenue - Boston Business Journal
The Business Journals· 1 day agoThe RSV vaccine will now be reviewed at the CDC's Advisory Committee on Immunization Practices...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Morningstar· 20 hours agoPfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman ...
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
Investor's Business Daily· 4 days agoBut it can be serious or even deadly in babies and older adults. Like rivals Pfizer and GSK — which...
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Reuters via AOL· 4 days agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 6 days agoDuring the March quarter, the U...projection. The company also raised its sales outlook for the...
US FDA advisers to consider if new COVID shots should target JN.1 variant By Reuters
Investing.com· 22 hours agoShares of Novavax (NASDAQ:NVAX) soared 11% in morning trade, after the documents were released. The...